This is a routine scientific update with no near-term catalyst for GNPX. Monitor for any future clinical development plans for REQORSA in neurodegenerative indications, but no actionable trading signal from this filing alone.
Price Chart
Executive Summary
Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in brain aging, published in Mechanisms of Ageing and Development. The study found TUSC2 loss disrupts mitochondrial function and protein homeostasis in the hippocampus, with sex-specific effects, and human data showed TUSC2 expression declines with age. This is exploratory preclinical research that does not evaluate REQORSA as a treatment for aging or neurodegeneration, and no financial data or clinical milestones are reported.
Key Facts
- New peer-reviewed mouse study published in Mechanisms of Ageing and Development identifies TUSC2's role in hippocampal aging and proteostasis
- TUSC2 expression declined significantly with age in 11 of 13 examined human brain regions, with additional reductions in Alzheimer's datasets
- The research did not evaluate REQORSA as a treatment for aging or neurodegenerative disease
- No financial data, clinical trial results, or regulatory milestones were reported in this filing
Financial Impact
No financial impact disclosed; exploratory preclinical research only
Risk Factors
- Preclinical findings may not translate to human therapeutic outcomes
- No current clinical program for TUSC2 in aging or neurodegeneration
- Company faces ongoing going-concern and capital-raising risks as noted in forward-looking statements
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-033053 |
| Document: 0001437749-26-033053-index-headers.html | 0001437749-26-033053 |
| Document: 0001437749-26-033053-index.html | 0001437749-26-033053 |
| Document: 0001437749-26-033053.txt | 0001437749-26-033053 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $2.05 | awaiting T+60 | — | $1.81 (−11.71%) |
Aug 18, 2026 9w ago | 8-K | $3.95 | awaiting T+60 | — | $1.81 (−54.18%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.81 (−61.89%) |
Jul 14, 2026 14w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.81 (−290.76%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.81 (+229.03%) |
May 26, 2026 21w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.81 (−89.34%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.81 (−90.44%) |
Apr 28, 2026 25w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.81 (−91.11%) |
Apr 21, 2026 26w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.81 (−92.45%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.81 (−9.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers